Trial · NCT07002827
Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.
NCT07002827, Not applicable, Recruiting, Institute of Liver and Biliary Sciences, India
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis. Trials, record NCT07002827. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07002827
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.
- NCT number
- NCT07002827
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Institute of Liver and Biliary Sciences, India
- Conditions
- Decompensated Liver Cirrhosis
- Interventions
- Darbepoetin, G-CSF, Lactulose, Albumin
- First posted
- 2025-06-04
- Last updated
- 2026-05-22
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in innate immunity between the groups. | 6 months | Innate immunity -Monocyte, neutrophils -distribution , function and bioenergetic adaptation |
| Secondary | Proportion of participants developed new-onset of LRE (such as ascites, HE, AKI, bleed and sepsis) or show mortality in all the groups. | 6 months | |
| Secondary | Cumulative incidence of second decompensation in all the groups. | 6 months & 1 year | |
| Secondary | Transplant-free survival. | 6 months & 1 year | |
| Secondary | Number of participants with improvement in liver disease severity indices (CTP). | 6 months | |
| Secondary | Number of participants with improvement in liver disease severity indices (MELD). | 6 months | |
| Secondary | Number of participants with change in adaptive immunity(T-cell, B-cell and NK cells distribution only ) | 6 months | |
| Secondary | Number of participants with change in inflammation (a panel of pro and anti-inflammatory cytokines). | 6 months | |
| Secondary | Change in gcsf levels and EPO levels at baseline and completion of each cycle. | 6 months | |
| Secondary | Proportion of participants completing treatment without major adverse effects; | 6 months |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07002827
GET https://conductscience.org/api/trials/v1/NCT07002827/registered